(Article 223-16 of General Regulation of the French financial markets authority)
PARIS, July 05, 2024 (GLOBE NEWSWIRE) —
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 06/30/2024 | 100,093,635 | 88,029,364 |
For further information on Cellectis, please contact:
Media contact:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contacts:
Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577
Attachment


Đề xuất
Spur Therapeutics To Present New Clinical Data on FLT201 for Gaucher Disease during the IWGGD 2026 Symposium
InnovAge to Announce Fiscal Third Quarter 2026 Financial Results and Host Conference Call Tuesday, May 5, 2026
Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair
Catheter Precision Secures U.S. Patent Allowance on Foundational Surgical Technology, Establishing Powerful IP and Accelerating Scalable Growth Strategy
3Trees Ranked No. 1 Globally by 2025 Stone Paint Sales Volume, Advancing International Strategy